Mixture Models and Subpopulation Classification: A Pharmacokinetic Simulation Study and Application to Metoprolol CYP2D6 Phenotype
暂无分享,去创建一个
[1] U. Gundert-Remy,et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations , 2004, European Journal of Clinical Pharmacology.
[2] R. Straka,et al. Analysis of metoprolol enantiomers in human serum by liquid chromatography on a cellulose-based chiral stationary phase. , 1990, Journal of chromatography.
[3] L. Bertilsson,et al. Polymorphic Drug Oxidation , 1996 .
[4] R. Straka,et al. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota , 1995, Clinical pharmacology and therapeutics.
[5] J. Tuomilehto,et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. , 1988, JAMA.
[6] Evaluation of Mixture Modeling with Count Data Using NONMEM , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[7] B. Burlew,et al. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[8] M. Ingelman-Sundberg,et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[9] J. Idle,et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. , 1980, Journal of medical genetics.
[10] K. Hoffmann,et al. Metabolism of metoprolol-(3-h) in man, the dog and the rat. , 1975, Acta pharmacologica et toxicologica.
[11] J. Staessen,et al. Primary Prevention With Metoprolol in Patients With Hypertension , 1988 .
[12] M. Ingelman-Sundberg,et al. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population , 1992, Clinical pharmacology and therapeutics.
[13] R. Morris,et al. Population Pharmacokinetics of Perhexiline From Very Sparse, Routine Monitoring Data , 2001, Therapeutic drug monitoring.
[14] D. Perrier,et al. Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients , 2004, European Journal of Clinical Pharmacology.
[15] C. Meisel,et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol Pharmacokinetics and Pharmacodynamics , 2004, Clinical pharmacology and therapeutics.
[16] M. Ingelman-Sundberg,et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.
[17] A. Nafziger,et al. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. , 2000, Pharmacogenetics.
[18] L. Bertilsson,et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.
[19] I. Zineh,et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension , 2004, Clinical pharmacology and therapeutics.
[20] G. Tucker,et al. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. , 1988, The Journal of pharmacology and experimental therapeutics.
[21] B. Frame,et al. Population Pharmacokinetics of Ceftizoxime Administered by Continuous Infusion in Clinically Ill Adult Patients , 1998, Antimicrobial Agents and Chemotherapy.